Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.

Cardiovascular toxicology - 1 Jan 2021

Vaitiekus Domas, Muckiene Gintare, Vaitiekiene Audrone, Sereikaite Liveta, Inciuraite Ruta, Insodaite Ruta, Cepuliene Daiva, Kupcinskas Juozas, Ugenskiene Rasa, Jurkevicius Renaldas, Juozaityte Elona

Abstract excerpt

Progress in oncology has allowed to improve outcomes in many breast cancer patients. The core stone of breast cancer chemotherapy is anthracycline-based chemotherapy. Unfortunately, anthracyclines cause cardiotoxicity which is a limiting factor of its use and lifetime cumulative dose of anthracyclines is the major risk factor for cardiotoxicity. With evolution of echocardiography subclinical damage is identified,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cardiotoxicity

Share to Heart Diseases

Share to Hemochromatosis Protein

Share to Risk Assessment

Share to Risk Factors

Source

Identifiers

PMID: 32748118
DOI: 10.1007/s12012-020-09595-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.PMID 32748118Read ↗

Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer PatientsSemantic proximity Read ↗

Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation.Semantic proximity Read ↗

Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologistSemantic proximity Read ↗

Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study.Semantic proximity Read ↗

Genetic factors in the pathogenesis of cardio-oncology.Semantic proximity Read ↗

The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.Semantic proximity Read ↗

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.Semantic proximity Read ↗

HFE H63D mutation frequency shows an increase in Turkish women with breast cancer.Semantic proximity Read ↗

Different Mechanisms in Doxorubicin-induced Cardiomyopathy: Impact of BRCA1 and BRCA2 MutationsSemantic proximity Read ↗

Differential Genetic and Morphofunctional Patterns of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients with Pre-existing HypertensionSemantic proximity Read ↗

Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.Semantic proximity Read ↗

The association between early‐onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple‐negative breast cancer patients and some novel autophagy‐related polymorphisms in their genomic DNA: a real‐world studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.